Table 3.

Odds ratios and 95% confidence intervals of prostate cancer according to baseline serum creatinine, stratified by selected characteristics

No. cases/controlsP trend
OR (95% CI) by quartile of serum creatinine
Q1Q2Q3Q4
Age (y)
    <6119/5524/5632/4322/46
1*1.25 (0.59-2.64)2.65 (1.25-5.61)1.54 (0.70-3.38)0.13
    ≥6125/6229/7323/5550/62
11.07 (0.56-2.04)1.08 (0.54-2.17)2.38 (1.26-4.51)0.005
Cigarettes/d
    <2020/5022/5224/4238/57
11.13 (0.52-2.43)1.51 (0.70-3.27)2 (0.97-4.14)0.04
    ≥2024/6731/7731/5634/51
11.07 (0.56-2.04)1.56 (0.79-3.06)1.96 (0.97-3.92)0.03
Height (cm)
    <17423/6832/5420/4828/52
11.79 (0.90-3.58)1.17 (0.56-2.47)1.67 (0.83-3.38)0.10
    ≥17420/4921/7535/5044/56
10.74 (0.35-1.54)1.99 (0.97-4.08)2.20 (1.08-4.49)0.003
Body mass index (kg/m2)
    <2625/6120/6124/5030/54
10.80 (0.38-1.67)1.29 (0.63-2.68)1.70 (0.83-3.48)0.08
    ≥2618/5633/6831/4842/54
11.45 (0.72-2.91)1.98 (0.96-4.09)2.41 (1.19-4.88)0.01
Disease stage
    Nonaggressive23/7130/5724/4637/53
11.76 (0.91-3.40)1.91 (0.95-3.86)2.71 (1.34-5.48)0.006
    Aggressive20/4623/7130/5035/54
10.84 (0.39-1.81)1.66 (0.78-3.51)1.84 (0.83-4.11)0.04
Follow-up time (y)
    <5
10.61 (0.25-1.51)1.12 (0.48-2.62)2.00 (0.78-5.11)0.09
    ≥5
11.70 (0.91-3.17)2.09 (1.08- 4.05)2.44 (1.28- 4.65)0.007
History of BPH
    No41/10849/12750/9665/97
11.08 (0.66-1.78)1.49 (0.89-2.49)2.00 (1.21-3.30)0.003
    Yes3/94/25/27/11
12.93 (0.16-52.82)9.81 (0.33-288.22)1.11 (0.12-10.21)0.80
Diastolic blood pressure (mm Hg)
    <9029/6726/6527/6337/59
10.97 (0.50-1.88)1.01 (0.52-1.96)1.71 (0.89-3.28)0.11
    ≥9015/5027/6428/3535/49
11.56 (0.73-3.37)3.35 (1.49-7.56)3.09 (1.41-6.80)0.002
Systolic blood pressure (mm Hg)
    <14019/5221/4924/4330/48
11.32 (0.60-2.90)1.77 (0.81-3.85)1.97 (0.91-4.24)0.06
    ≥14025/6532/8031/5542/60
11.09 (0.58-2.07)1.62 (0.84-3.15)2.20 (1.15-4.2)0.01
History of hypertension
    No38/9540/10545/8354/83
11 (0.58-1.71)1.43 (0.83-2.47)1.85 (1.08-3.16)0.01
    Yes6/2213/2410/1518/25
15.42 (1.35-21.81)4.26 (1.00-18.12)3.88 (1.02-14.68)0.11
α-Tocopherol supplementation
    No24/7537/8228/6045/52
11.48 (0.79-2.75)1.53 (0.78-2.99)3.36 (1.74-6.46)0.0003
    Yes20/4216/4727/3827/56
10.71 (0.31-1.61)1.47 (0.67-3.23)1.02 (0.47-2.21)0.66
β-Carotene supplementation
    No19/4922/5622/4636/48
11.01 (0.48-2.14)1.35 (0.63-2.89)2.46 (1.17-5.14)0.01
    Yes25/6831/7333/5236/60
11.21 (0.64-2.31)1.90 (0.98-3.69)1.82 (0.95-3.48)0.04
Serum α-tocopherol (mg/L)
    <11.7523/6531/7133/4536/44
11.29 (0.66-2.49)2.28 (1.14-4.56)2.55 (1.28-5.1)0.003
    ≥11.7521/5222/5822/5336/64
10.99 (0.47-2.09)1.29 (0.61-2.73)1.82 (0.90-3.67)0.06
Serum homocysteine (nmol/mL)
    <11.831/7121/7226/5026/33
10.67 (0.34-1.33)1.22 (0.62-2.40)1.96 (0.96-3.98)0.04
    ≥11.813/4632/5729/4846/75
11.95 (0.89-4.25)2.18 (0.98-4.87)2.43 (1.13-5.20)0.03
Proteine intake (g/d)
    <9123/5723/6626/3840/56
10.85 (0.41-1.77)2.06 (0.98-4.35)1.86 (0.94-3.69)0.02
    ≥9116/5629/5927/5730/43
11.77 (0.84-3.76)1.77 (0.82-3.86)3.38 (1.49-7.67)0.005
Alcohol intake (g ethanol/d)
    <9.323/5229/5629/4638/59
11.24 (0.62-2.49)1.39 (0.68-2.86)1.55 (0.79-3.07)0.20
    ≥9.316/6123/6924/4932/40
11.29 (0.59-2.79)1.98 (0.89-4.39)3.03 (1.34-6.82)0.004
  • *Unconditioned logistic regression models, adjusting for age at randomization, clinic, intervention group, date of baseline blood draw, serum homocysteine, and family history of prostate cancer.